Analysts Anticipate Collegium Pharmaceutical Inc (NASDAQ:COLL) Will Announce Earnings of $0.35 Per Share

Share on StockTwits

Wall Street analysts expect Collegium Pharmaceutical Inc (NASDAQ:COLL) to announce $0.35 earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Six analysts have issued estimates for Collegium Pharmaceutical’s earnings. The lowest EPS estimate is $0.09 and the highest is $0.63. Collegium Pharmaceutical reported earnings of ($0.05) per share in the same quarter last year, which indicates a positive year over year growth rate of 800%. The firm is scheduled to report its next quarterly earnings report on Wednesday, May 13th.

On average, analysts expect that Collegium Pharmaceutical will report full-year earnings of $2.62 per share for the current year, with EPS estimates ranging from $1.20 to $3.41. For the next fiscal year, analysts forecast that the business will post earnings of $3.47 per share, with EPS estimates ranging from $2.42 to $4.00. Zacks’ earnings per share calculations are an average based on a survey of sell-side research firms that that provide coverage for Collegium Pharmaceutical.

Collegium Pharmaceutical (NASDAQ:COLL) last released its earnings results on Thursday, February 27th. The specialty pharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.17) by $0.10. The firm had revenue of $74.20 million during the quarter, compared to analysts’ expectations of $73.31 million. Collegium Pharmaceutical had a negative return on equity of 26.43% and a negative net margin of 7.66%. The company’s revenue was up 1.0% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.27 EPS.

COLL has been the subject of a number of research reports. Piper Sandler increased their target price on Collegium Pharmaceutical from $27.00 to $35.00 and gave the stock an “overweight” rating in a report on Wednesday, February 12th. Needham & Company LLC increased their target price on Collegium Pharmaceutical from $36.00 to $38.00 and gave the stock a “buy” rating in a report on Friday, February 7th. ValuEngine cut Collegium Pharmaceutical from a “buy” rating to a “hold” rating in a report on Tuesday, January 7th. William Blair reiterated a “buy” rating on shares of Collegium Pharmaceutical in a report on Friday, February 28th. Finally, Jefferies Financial Group initiated coverage on Collegium Pharmaceutical in a report on Wednesday, February 19th. They set a “buy” rating and a $43.00 target price for the company. One research analyst has rated the stock with a sell rating, two have given a hold rating and eight have given a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $31.38.

In other news, EVP Scott Dreyer sold 1,321 shares of the firm’s stock in a transaction dated Tuesday, January 14th. The stock was sold at an average price of $23.87, for a total value of $31,532.27. Following the completion of the transaction, the executive vice president now owns 35,716 shares in the company, valued at approximately $852,540.92. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Michael Thomas Heffernan sold 295,287 shares of the firm’s stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $21.93, for a total value of $6,475,643.91. Following the completion of the transaction, the director now owns 402,086 shares of the company’s stock, valued at approximately $8,817,745.98. The disclosure for this sale can be found here. 8.08% of the stock is owned by company insiders.

Institutional investors have recently bought and sold shares of the stock. Great West Life Assurance Co. Can bought a new position in Collegium Pharmaceutical during the fourth quarter worth about $46,000. SG Americas Securities LLC bought a new position in Collegium Pharmaceutical during the fourth quarter worth about $125,000. AQR Capital Management LLC bought a new position in Collegium Pharmaceutical during the fourth quarter worth about $237,000. Campbell & CO Investment Adviser LLC grew its holdings in Collegium Pharmaceutical by 17.4% during the fourth quarter. Campbell & CO Investment Adviser LLC now owns 11,875 shares of the specialty pharmaceutical company’s stock worth $244,000 after purchasing an additional 1,764 shares during the period. Finally, Prospera Financial Services Inc bought a new position in Collegium Pharmaceutical during the fourth quarter worth about $283,000. Institutional investors and hedge funds own 91.95% of the company’s stock.

COLL stock opened at $17.03 on Friday. The stock has a 50-day moving average price of $20.72 and a two-hundred day moving average price of $18.04. The stock has a market cap of $594.41 million, a PE ratio of -25.04, a price-to-earnings-growth ratio of 0.31 and a beta of 0.54. The company has a current ratio of 1.27, a quick ratio of 1.22 and a debt-to-equity ratio of 0.20. Collegium Pharmaceutical has a 1 year low of $10.01 and a 1 year high of $25.59.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and misuse, including chewing, crushing, heating, and injecting.

See Also: Why is cost of goods sold important?

Get a free copy of the Zacks research report on Collegium Pharmaceutical (COLL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Mitchell Mcleod Pugh & Williams Inc. Acquires 500 Shares of Starbucks Co.
Mitchell Mcleod Pugh & Williams Inc. Acquires 500 Shares of Starbucks Co.
Bank of America  PT Lowered to $20.00 at UBS Group
Bank of America PT Lowered to $20.00 at UBS Group
IFM Investors Pty Ltd Sells 5,253 Shares of Walmart Inc
IFM Investors Pty Ltd Sells 5,253 Shares of Walmart Inc
Macquarie Group Ltd. Has $2.83 Million Position in Valero Energy Co.
Macquarie Group Ltd. Has $2.83 Million Position in Valero Energy Co.
Marquette Asset Management LLC Increases Stock Position in Boeing Co
Marquette Asset Management LLC Increases Stock Position in Boeing Co
AT&T Inc.  Shares Sold by IFM Investors Pty Ltd
AT&T Inc. Shares Sold by IFM Investors Pty Ltd


© 2006-2020 Ticker Report